Terns Pharmaceuticals Stock Soars 10% After Positive Phase 1 Trial Results Showing 5.5% Weight Loss

Sep 9, 2024, 11:09 AM

Terns Pharmaceuticals has announced positive Phase 1 clinical trial results for its once-daily oral GLP-1R agonist, TERN-601, aimed at treating obesity. The trial demonstrated a statistically significant mean weight loss of up to 5.5% over 28 days, with a 4.9% placebo-adjusted weight loss. The study also reported the absence of treatment-related dose interruptions, reductions, or discontinuations, with mostly mild adverse events, despite aggressive titration to high doses. Following this announcement, Terns Pharmaceuticals' stock soared by 10%.